Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

Phase 2positiveRademikibartPositive

AI Analysis

Summary

Connect Biopharma announced positive preliminary topline data from its global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and Type 2 inflammation.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Positive preliminary topline data from global Phase 2 study

Importance:7/10

Sentiment:

0.75

Phase 2COPDType 2 inflammationPositive dataAdd-on treatment

Related Companies

$CNTB

Read the original article

Published by yahoo_finance on September 30, 2026 11:00 AM

Read Original